NASDAQ:XOMA XOMA (XOMA) Stock Price, News & Analysis $29.51 +0.01 (+0.03%) (As of 10/25/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About XOMA Stock (NASDAQ:XOMA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get XOMA alerts:Sign Up Key Stats Today's Range$29.36▼$30.0050-Day Range$25.48▼$29.8552-Week Range$14.27▼$30.50Volume36,299 shsAverage Volume20,811 shsMarket Capitalization$345.27 millionP/E RatioN/ADividend YieldN/APrice Target$78.50Consensus RatingBuy Company OverviewXOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.Read More… Trump or Kamala? It may come down to this strange twist… (Ad)Could this be the key to America's second coming? A strange resurrection born in the hollers of Appalachia? To uncover the full story and learn how you can potentially profit from it...watch my new documentary here. XOMA Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks84th Percentile Overall ScoreXOMA MarketRank™: XOMA scored higher than 84% of companies evaluated by MarketBeat, and ranked 241st out of 998 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingXOMA has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageXOMA has only been the subject of 1 research reports in the past 90 days.Read more about XOMA's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for XOMA are expected to grow in the coming year, from ($1.42) to ($0.59) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of XOMA is -11.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of XOMA is -11.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioXOMA has a P/B Ratio of 3.82. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about XOMA's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.94% of the outstanding shares of XOMA have been sold short.Short Interest Ratio / Days to CoverXOMA has a short interest ratio ("days to cover") of 10.4, which indicates bearish sentiment.Change versus previous monthShort interest in XOMA has recently decreased by 7.52%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldXOMA does not currently pay a dividend.Dividend GrowthXOMA does not have a long track record of dividend growth. Sustainability and ESG3.0 / 5Environmental Score-0.22 Percentage of Shares Shorted1.94% of the outstanding shares of XOMA have been sold short.Short Interest Ratio / Days to CoverXOMA has a short interest ratio ("days to cover") of 10.4, which indicates bearish sentiment.Change versus previous monthShort interest in XOMA has recently decreased by 7.52%, indicating that investor sentiment is improving significantly. News and Social Media3.2 / 5News Sentiment0.78 News SentimentXOMA has a news sentiment score of 0.78. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for XOMA this week, compared to 1 article on an average week.Search Interest1 people have searched for XOMA on MarketBeat in the last 30 days. MarketBeat Follows2 people have added XOMA to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, XOMA insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.20% of the stock of XOMA is held by insiders.Percentage Held by Institutions95.92% of the stock of XOMA is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about XOMA's insider trading history. Receive XOMA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for XOMA and its competitors with MarketBeat's FREE daily newsletter. Email Address XOMA Stock News HeadlinesXOMA's (XOMA) "Buy" Rating Reiterated at HC WainwrightOctober 24 at 5:41 AM | americanbankingnews.comXoma enters $15M royalty monetization arrangement with Twist BioscienceOctober 22 at 4:46 PM | markets.businessinsider.comTrump vs. Kamala - results are in…If you missed it, my emergency election broadcast is now available - but will be removed soonOctober 25, 2024 | Porter & Company (Ad)Xoma’s Strategic Partnerships and Pipeline Growth Position It as a Strong Investment OpportunityOctober 22 at 4:46 PM | markets.businessinsider.comXOMA Royalty Significantly Expands its Royalty and Milestone Portfolio with the Addition of Over 60 Early-Stage Programs from Twist BioscienceOctober 22 at 8:00 AM | globenewswire.comXOMA Stock Dips Amidst Biotech Sector DeclineOctober 3, 2024 | gurufocus.comXOMA Poised for Growth: FDA Approval of Miplyffa and Strategic Acquisitions Underpin Buy RatingSeptember 25, 2024 | markets.businessinsider.comZevra's MIPLYFFA™ (arimoclomol) Receives Approval from U.S. Food and Drug Administration for Use in Patients with Niemann-Pick Disease Type C (NPC)September 23, 2024 | globenewswire.comSee More Headlines XOMA Stock Analysis - Frequently Asked Questions How have XOMA shares performed this year? XOMA's stock was trading at $18.50 on January 1st, 2024. Since then, XOMA stock has increased by 59.5% and is now trading at $29.51. View the best growth stocks for 2024 here. How were XOMA's earnings last quarter? XOMA Co. (NASDAQ:XOMA) posted its earnings results on Tuesday, August, 13th. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.26) by $0.02. The biotechnology company had revenue of $11.09 million for the quarter, compared to analysts' expectations of $8.37 million. XOMA had a negative trailing twelve-month return on equity of 24.50% and a negative net margin of 128.59%. Who are XOMA's major shareholders? Top institutional shareholders of XOMA include Ellsworth Advisors LLC (0.17%). Insiders that own company stock include Bvf Partners L P/Il, James R Neal, Thomas M Burns, Bradley Sitko and Owen Hughes. View institutional ownership trends. How do I buy shares of XOMA? Shares of XOMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of XOMA own? Based on aggregate information from My MarketBeat watchlists, some other companies that XOMA investors own include American Water Works (AWK), Waste Connections (WCN), AUO (AUOTY), The RMR Group (RMR), Voyager Therapeutics (VYGR), DiamondRock Hospitality (DRH) and iShares Micro-Cap ETF (IWC). Company Calendar Last Earnings8/13/2024Today10/25/2024Next Earnings (Estimated)11/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:XOMA CUSIP98419J10 CIK791908 Webwww.xoma.com Phone(510) 204-7200Fax510-649-7571Employees10Year Founded1981Price Target and Rating Average Stock Price Target$78.50 High Stock Price Target$117.00 Low Stock Price Target$40.00 Potential Upside/Downside+164.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($2.49) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-40,830,000.00 Net Margins-128.59% Pretax Margin-119.61% Return on Equity-24.50% Return on Assets-11.24% Debt Debt-to-Equity Ratio1.15 Current Ratio8.71 Quick Ratio8.71 Sales & Book Value Annual Sales$4.76 million Price / Sales73.08 Cash FlowN/A Price / Cash FlowN/A Book Value$7.72 per share Price / Book3.85Miscellaneous Outstanding Shares11,700,000Free Float10,861,000Market Cap$347.84 million OptionableOptionable Beta0.92 Social Links 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report This page (NASDAQ:XOMA) was last updated on 10/25/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe secret supplier behind NVIDIA, Tesla and MicrosoftThe Biggest AI firms in the world...Tesla... Microsoft... NVIDIA... Are all relying on a little-known suppl...Behind the Markets | SponsoredYour financial planner would NEVER tell you thisYour Financial Planner Won't Tell You About This Investment Strategy Silicon Valley insider Jeff Brown has ...Brownstone Research | SponsoredNext opportunity for crypto millions"Uptober" is here, and it's not just a clever name. Historically, October ignites crypto's most explosive g...Crypto 101 Media | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored“Hear That Whoosh Sound? It’s the Great Power Suck of 2025”We’re coming to the end of the line for the traditional energy grid. Look what’s happening in California.Traders Agency | SponsoredInvest in the company that won over the DragonsThe pioneer in smart-doorbell technology, RING, pitched their business on the hit show Shark Tank at a valuati...RYSE | SponsoredPutin proposes new currencyRussian leader Vladimir Putin just unveiled the first physical mockup of a proposed new currency. Many spec...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding XOMA Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share XOMA With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.